Using its integrated chemical and pharmaceutical development platform, EVOdevelop, Evotec OAI will complete the full validation of the process to AMD 3100, including process R&D, analytical work and cGMP manufacturing, and will be responsible for producing the relevant documentation for subsequent dossier filing.
“We believe AMD3100 has great potential to help cancer patients undergo successful stem cell transplantation and we recently announced the start of phase III clinical studies in January 2005,” said Dr Renato Skerlj, vice president of chemistry at Anormed.
“In support of this phase III program we have selected Evotec OAI to complete the full validation of the process for AMD3100. This decision was based on the positive work experience we have had with Evotec OAI since 2003 resulting in both the successful and reliable completion of a number of Anormed development projects,” Skerlj continued.